Twist Bioscience Revenue Growth Rates (TWST), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Twist Bioscience Corporation  (NASDAQ: TWST)
 

TWST's Revenue Growth by Quarter and Year

Twist Bioscience's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TWST Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter September -
3rd Quarter June 118.38
2nd Quarter March 110.72
1st Quarter December 103.70
FY 332.80

TWSTs Annual Revenue
Twist Bioscience's Revenue in the fiscal year 2025 $ 376.57 millions
Twist Bioscience's Revenue in the fiscal year 2024 $ 312.97 millions
Twist Bioscience's Revenue in the fiscal year 2023 $ 245.11 millions
Twist Bioscience's Revenue in the fiscal year 2022 $ 203.57 millions
Twist Bioscience's Revenue in the fiscal year 2021 $ 132.33 millions




TWST Revenue third quarter 2026 Y/Y Growth Comment
Twist Bioscience Corporation reported Revenue improvement of 23.23% year on year in the third quarter 2026, to $ 118.38 millions, this is lower than Twist Bioscience Corporation's recent average Revenue rise of 46.18%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Revenue growth. While Twist Bioscience Corporation' s Revenue rise of 23.23% ranks overall at the positon no. 920 in the third quarter 2026.


TWST Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter September - 16.88 % 26.53 % 16.82 %
3rd Quarter June 23.23 % 17.92 % 27.8 % 13.6 %
2nd Quarter March 19.32 % 23.23 % 25.12 % 25.04 %
1st Quarter December 16.9 % 24.07 % 31.82 % 29.08 %
FY   - 20.32 % 27.69 % -

Financial Statements
Twist Bioscience's third quarter 2026 Revenue $ 118.38 millions TWST's Income Statement
Twist Bioscience's third quarter 2025 Revenue $ 96.06 millions Quarterly TWST's Income Statement


TWST Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter September - 3.07 % 3.99 % 5.04 %
3rd Quarter June 6.91 % 3.52 % 8.18 % 5.92 %
2nd Quarter March 6.77 % 4.6 % 5.31 % 10.95 %
1st Quarter December 4.74 % 4.72 % 6.8 % -5.36 %
FY (Year on Year)   - 20.32 % 27.69 % -


Back to TWST Growth rate Comparisons >> Back to TWST Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #189
Overall #920

Revenue Y/Y Growth Statistics
High Average Low
166.45 % 46.18 % 13.59 %
(Sep 30 2019)   (Mar 31 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #189
Overall #920
Revenue Y/Y Growth Statistics
High Average Low
166.45 % 46.18 % 13.59 %
(Sep 30 2019)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Twist Bioscience's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
94.47 % 11.46 % -13.17 %
(Sep 30 2018)  


TWST's III. Quarter Q/Q Revenue Comment
Twist Bioscience Corporation achieved in the III. Quarter 2026 below company average Revenue increase of 6.91% quarter on quarter, to $ 118.38 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 3.52% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Twist Bioscience's Revenue growth quarter on quarter, overall rank is 1009.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #150
Overall #1009
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #150
Overall #1009
Revenue Q/Q Growth Statistics
High Average Low
94.47 % 11.46 % -13.17 %
(Sep 30 2018)  


TWST's III. Quarter Q/Q Revenue Comment
Twist Bioscience Corporation achieved in the III. Quarter 2026 below company average Revenue increase of 6.91% quarter on quarter, to $ 118.38 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 3.52% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Twist Bioscience's Revenue growth quarter on quarter, overall rank is 1009.


Twist Bioscience's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 431.80 $ 409.48 $ 391.56 $ 376.57 $ 362.27
Y / Y Revenue Growth (TTM) 19.19 % 17.77 % 18.59 % 20.32 % 22.72 %
Year on Year Revenue Growth Overall Ranking # 751 # 616 # 465 # 332 # 83
Seqeuential Revenue Change (TTM) 5.45 % 4.58 % 3.98 % 3.95 % 4.2 %
Seq. Revenue Growth (TTM) Overall Ranking # 2173 # 1801 # 1646 # 1227 # 428


Cumulative Revenue growth Comment
Although Twist Bioscience's Annual Revenue growth year on year were below company's average 40.43% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 19.19% year on year, from 17.77% in Mar 31 2026.

In the Healthcare sector 153 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 616 to 751.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 154
Overall # 751

Revenue TTM Y/Y Growth Statistics
High Average Low
82.87 %
 40.43 %
17.77 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 321
S&P 500 # 2173
Cumulative Revenue growth Comment
Although Twist Bioscience's Annual Revenue growth year on year were below company's average 40.43% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 19.19% year on year, from 17.77% in Mar 31 2026.

In the Healthcare sector 153 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 616 to 751.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 154
Overall # 751

Revenue TTM Y/Y Growth Statistics
High Average Low
82.87 %
40.43 %
17.77 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 321
S&P 500 # 2173




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TWST's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions
Quanterix Corporation35.42%$ 35.416 millions
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions
Biocryst Pharmaceuticals Inc 33.61%$ 33.606 millions
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions


About Twist Bioscience Revenue Growth Rates (TWST), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Twist Bioscience Corp (CIK 1581280).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001581280-26-000047
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Twist Bioscience Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.